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Background: The infection with Borrelia burgdorferi can result in acute to chronic Lyme disease. In addition,
coinfection with tick-borne pathogens, Babesia species and Anaplasma phagocytophilum has been increasing in
endemic regions of the USA and Europe. The currently used serological diagnostic tests are often difficult to
interpret and, moreover, antibodies against the pathogens persist for a long time making it difficult to confirm the
cure of the disease. In addition, these tests cannot be used for diagnosis of early disease state before the adaptive
immune response is established. Since nucleic acids of the pathogens do not persist after the cure, DNA-based
diagnostic tests are becoming highly useful for detecting infectious diseases.
Results: In this study, we describe a real-time multiplex PCR assay to detect the presence of B. burgdorferi, B. microti
and A. phagocytophilum simultaneously even when they are present in very low copy numbers. Interestingly, this
quantitative PCR technique is also able to differentiate all three major Lyme spirochete species, B. burgdorferi,
B. afzelii, and B. garinii by utilizing a post-PCR denaturation profile analysis and a single molecular beacon probe.
This could be very useful for diagnosis and discrimination of various Lyme spirochetes in European countries where
all three Lyme spirochete species are prevalent. As proof of the principle for patient samples, we detected the
presence of low number of Lyme spirochetes spiked in the human blood using our assay. Finally, our multiplex
assay can detect all three tick-borne pathogens in a sensitive and specific manner irrespective of the level of each
pathogen present in the sample. We anticipate that this novel diagnostic method will be able to simultaneously
diagnose early to chronic stages of Lyme disease, babesiosis and anaplasmosis using the patients’ blood samples.
Conclusion: Real-time quantitative PCR using specific primers and molecular beacon probes for the selected
amplicon described in this study can detect three tick-borne pathogens simultaneously in an accurate manner.
Keywords: Borrelia burgdorferi, Anaplasma phagocytophilum, Babesia microti, Tick-borne emerging pathogens,
Real-time PCR, Molecular beacons, Multiplex assay, Lyme disease, Babesiosis, AnaplasmosisBackground
Ixodes species of ticks are responsible for transmitting
Lyme disease causing Borrelia burgdorferi and several
other pathogens both in the North America and Europe
[1,2]. Recently, a press release by Centers for Disease
Control and Prevention (CDC) stated that only one
tenth (~30,000) of the actual Lyme disease cases, i.e.,
300,000, are reported in the United States every year.
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stated.have also shown that in addition to Lyme spirochetes,
ticks are often coinfected with the obligate intracellular
bacterium, Anaplasma phagocytophilum, and a proto-
zoan parasite belonging to the genus, Babesia with B.
microti prevalent in the United States and B. divergens
in Europe [2-9]. These two are emerging tick-borne
pathogens and cause increasing number of infections in the
local populations in the endemic zones. A. phagocytophilum
is the etiological agent of human granulocytic anaplasmosis
(HGA) that can manifest as moderate to life-threatening
disease in humans. The bacterium preferentially infects
granulocytes/neutrophils and persists in polymorphonu-
clear leukocytes (PMNs), causing thrombocytopenia andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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patients susceptible to secondary opportunistic infec-
tions. Human babesiosis is an intraerythrocytic infec-
tion that may remain asymptomatic but often leads to
severe to fatal disease [10]. Sensitive diagnostic tests
that can accurately and simultaneously diagnose Lyme
disease, anaplasmosis and babesiosis are not currently
available emphasizing a need to develop individual
test for each pathogen or a combinatorial test for all
three tick-borne pathogens to detect coinfection in
patients.
B. burgdorferi, A. phagocytophilum and B. microti have
overlapping epidemiology and transmission cycles with
shared tick vectors, and common primary and secondary
host reservoirs. All three use white-footed mice as a
reservoir host and white-tailed deer populations to
spread through the endemic regions of the United States
[11-14]. HGA and canine granulocytic anaplasmosis, as
well as bovine and human babesiosis, are prevalent in
Northeastern and Midwestern regions of the United
States, as is Lyme disease [8,10,15-23]. Severe to fatal
babesiosis cases have been reported in the USA in the
past two decades [24,25]. More recently, A. phagocyto-
philum infections have also increased significantly in
regions endemic for Lyme disease, with 3,637 HGA
cases reported by the CDC in the United States between
2003 and 2008 [26]. The CDC has now declared HGA
to be a notifiable disease [26]. In 2002, most commonly
diagnosed coinfections in patients in the Eastern parts of
the United States were due to B. burgdorferi and B.
microti, accounting for ~80% of the total tick-borne
coinfections. These coinfections exhibit more severe
clinical symptoms than infections by B. burgdorferi and
parasite B. microti alone probably as a consequence of
the modification of the immune system by the latter
[20,27]. Coinfections are also prevalent among ticks in
Europe and are also becoming common in humans, who
are regularly exposed to these ticks [28-30]. Hence, there
is a desperate need to develop assays for the detection of
pathogens responsible for these diseases individually
or together.
Accurate diagnosis of various tick-borne diseases is
problematic, due to similar clinical manifestations
[12,31]. Currently available serological tests are neither
cost-effective, nor sensitive or specific for diagnosis of
infections by these three pathogens transmitted by ticks,
especially at early stage of infection [9,32-34]. CDC
recommends two-tier serological tests with an enzyme-
linked immunosorbent assay (ELISA) or indirect im-
munofluorescence assay (IFA) as primary test followed
by the more specific Western blot analysis to confirm
diagnosis of Lyme disease [35]. Subjective interpretation
of the immunoblots further diminishes accuracy of the
test with only 70-80% serological test efficiency notedfor diagnosis of Lyme disease. However, accuracy of a
single C6 ELISA test sensitivity is reported to be slightly
higher for Lyme disease than the two-tier serological test
[27]. The positive predictive value of these serological
tests depends both on the prevalence of the disease in
the area, and on the sensitivity and specificity of the test.
Moreover, their predictive value varies among different
laboratories depending on which commercial kit is used
[36-38]. Furthermore, antibodies persist in the patients
long after the disease is cured such that serological tests
cannot be used as a test of cure. In addition, it is difficult
to assess reinfection in the endemic regions. PCR-based
assays have been tried for the diagnosis of Lyme disease,
but, by virtue of their design, they have had only a
limited level of success [39-41]. A. phagocytophilum and
B. microti infect white and red blood cells, respectively,
but are not easily detectable in blood. This offers add-
itional risk since they can also be transmitted through
blood transfusions and potentially vertically from mother
to infant [19,42-44]. The presence of Babesia species is
usually visualized by microscopic examination after
Giemsa staining; however, it is frequently overlooked,
because of the infection of less than 1% of erythrocytes
or due to hemolysis during the sample transport. Higher
parasitemia due to Babesia infection is usually fatal.
Serological tests and PCR have been found to be more
sensitive for its detection [45,46]. Microscopic detection
of A. phagocytophilum morulae in blood smears is also
difficult because <0.1% of neutrophils may show their
presence [47]. Like B. burgdorferi, A. phagocytophilum
lacks lipopolysaccharides and displays a large number of
immunogenic proteins on the bacterial surface, making
serological tests feasible. However, similar to Lyme
disease, serodiagnosis of HGA fails to detect active
disease [34,48,49]. Therefore, an assay that can identify
these two tick-borne pathogens, in addition to detecting
Lyme spirochetes will be ideal, cost-effective and will
facilitate design of proper treatment strategies for bac-
teria versus parasite.
Due to the presence of nucleases in the serum, nucleic
acids of the pathogens do not persist in the host much
longer after the disease is cured [50]. Therefore, PCR
and other nucleic acids-based assays have been used as
test of cure for a variety of infectious diseases [51-53].
Selection of proper PCR targets and conditions along
with the use of efficient detection probes are critical for
the development of sensitive and specific diagnostic
assays. Molecular beacons are hairpin-shaped oligonu-
cleotide probes that are highly specific for their target
sequences and can be labeled with distinguishably colored
fluorophores [54]. The single-stranded loop of molecular
beacons is designed to be complementary to a unique
gene sequence that identifies the infectious agent.
Drs. Marras, Tyagi, and Kramer used these probes to
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nucleotide polymorphism (SNPs) [55,56]. The basis of
this extraordinary specificity is that hairpin-shaped
probes can assume two different stable states, by: (i)
forming double-stranded hybrids with their target se-
quence, or (ii) retaining their partially double-
stranded structure when not bound to a target. Any
mismatch between the probe sequence of the molecu-
lar beacon and the target sequence destabilizes the
probe-target hybrid, leading to return of the molecu-
lar beacon in its stable hairpin structure [57,58]. Unlike
hairpin-shaped probes, linear probes such a TaqMan
probes have only one conformation, either on or off the
target. This decreases difference between the melting
temperature of a perfectly matched target sequence and a
single-nucleotide mismatched target sequence makes
discrimination between two scenarios more difficult to
discern [58-60]. Furthermore, Taqman probes are digested
by the endonuclease activity of the Taq polymerase in each
PCR cycle, such that optimization of both annealing and
digestion of the probe becomes more challenging in the
development of multiplex assays. Our success in utilizing
the extraordinary specificity of molecular beacon probes
to detect the recA gene of B. burgdorferi, and to quantitate
the number of spirochetes present in infected mouse
tissue [61] offered us an incentive to develop the assay for
diagnosis of Lyme disease in humans. We have now opti-
mized the assay to work in the presence of human DNA
for it to become useful as diagnostic test for human Lyme
disease. We describe here expansion of a simplified, highly
sensitive multiplex real-time PCR assay by incorporating
specific molecular beacons that can distinguish B. burg-
dorferi, A. phagocytophilum and B. microti simultaneously.
Application of this assay will make a significant difference
in achieving the rapid and accurate diagnosis of Lyme
disease, anaplasmosis and babesiosis in a cost-effective
manner.
Methods
Microbial strains and human cell line
For standardization of conditions for real-time PCR
diagnostic assay for Lyme disease, N40 strain clone D10/
E9 of B. burgdorferi (sensu stricto), VS461 strain of B.
afzelii and PBi strain of B. garinii were grown in BSKII
medium supplemented with 6% rabbit serum at 33°C.
Dr. Edouard Vannier of Tufts Medical Center at Boston,
and Dr. Errol Fikrig of Yale University School of
Medicine generously provided the genomic DNA from
B. microti strain RM/NS and A. phagocytophilum strain
HZ, respectively. Human embryonic kidney 293 cells
were cultured in a 1:1 mix of DMEM (low glucose) and
Ham’s F12 medium (Life Technologies, NY) supple-
mented with 10% FBS to isolate human DNA used in
the assays.Isolation of B. burgdorferi and human genomic DNA
Total genomic DNA was isolated from the Lyme spiro-
chetes grown to a density of ~108 spirochetes/ml and
from 293 cells using the previously described protocols
[62,63] with two modifications. First, PLG-containing
tubes (Qiagen Sciences, MD) were used for phenol and
chloroform extraction, since they allow clean separation
of the top aqueous layer by decantation after centrifuga-
tion. Second, a final step of passing the DNA through
DNeasy kit columns (Qiagen Sciences, MD) was inclu-
ded to obtain good quality DNA for real-time PCR.
B. microti and A. phagocytophilum plasmid construction
Thiamine pyrophosphokinase gene of B. microti (BmTPK)
and APH1387 gene of A. phagocytophilum were amplified
from B. microti strain RM/NS and A. phagocytophilum
strain HZ, respectively, using primers listed in Table 1,
which are designed specifically for RM/NS and HZ strains
genes, respectively. Each PCR amplicon was cloned in
pCR-XL-TOPO vector (Life Technologies, NY). Plasmid
containing BmTPK or APH1387 gene was used as tem-
plate in real-time PCR assays.
Isolation of total DNA from blood and blood culture
To determine the sensitivity of detection of spirochetes
in blood, we inoculated ten-fold diluted spirochetes
starting from 104 in 1.5 ml human whole blood. Dupli-
cate sets of three replicates for each dilution were pre-
pared. Total DNA from one set of tubes was isolated
immediately while 1.5 ml BSKII medium with 6% rabbit
serum was added to the second set of tubes. Total DNA
from this set of tubes was isolated using the method
described above after incubation of the tubes at 33°C for
48 h. From 100 μl of total DNA suspension, 5 μl of
sample was used for real-time PCR. Unspun human
whole blood with EDTA was purchased from Biological
Specialty Corporation (Colmar, PA) through Fisher
Scientific. Experiment with the human blood was con-
ducted under the protocol of the corresponding author
approved by the Institutional Review Board of New
Jersey Medical School. DHHS Federal Wide Assurance
is provided to New Jersey Medical School for work in-
volving human samples. Since no patients participated
in this study, consent form was not needed.
Molecular beacon design
Design of molecular beacon probe to hybridize to the
recA gene of Lyme spirochetes and tagged with FAM
fluorophore and BHQ-1 quencher were described pre-
viously [61]. Other molecular beacon probes were
designed using the previously described strategies [64].
Briefly, molecular beacon probes for; ACTA1 gene
amplicon was tagged with Quasar 670 fluorophore and
BHQ-2 quencher, BmTPK amplicon with CAL Fluor
Table 1 Sequence of PCR primers and molecular beacon probes





RecF primer 5’ GTG GAT CTA TTG TAT TAG ATG AGG CTC TCG 3’ 30 66.1 222 bp
RecR primer 5’ GCC AAA GTT CTG CAA CAT TAA CAC CTA AAG 3’ 30 67.3
RecF3 primer 5’ GCA AGA GTT CAA ATA GAA AA 3’ 20 53.7 287 bp
RecR3 primer 5’ AAA GCT TTT GCA TAA ACA G 3’ 19 54.7
RecA3 probe 5’ CTG GCG GAT ATC CTA GGG GG CGC CAG 3’ 26 67.9 FAM/ BHQ-1
5BmicrotiTPK primer 5’ AAT ATT GTT GAA TGG GGA TAT TTG TG 3’ 26 64.2 600 bp
3BmicrotiTPK primer 5’ AAT AAT ATA GCT TTT CCA AAA TAT AAC TGA C 3’ 31 60.2
5BmTPK primer 5’ TGA GAG GAA CGA CCA TAG C 3’ 19 61.4 141 bp
3BmTPK primer 5’ CCA TCA GGT AAA TCA CAC GAA A 3’ 22 61.6
BmTPK probe 5’ CGC GTC GGT GTT GTT GAC CAG CGG CCG CG
GAC GCG 3’
35 61.5 CAL Fluor Orange 560/ BHQ-1
5ApAPH1387 primer 5’ ATG TAT GGT ATA GAT ATA GAG CTA AGT GA 3’ 29 57.8 1737 bp
3ApAPH1387 primer 5’ CTA ATA ACT TAG AAC ATC TTC ATC GTC AG 3’ 29 62.2
5Aphagocyt primer 5’ ATG GCT ACT ACG AAG GAT 3’ 18 57.9 152 bp
3Aphagocyt primer 5’ CGA AGC AAC ATC TCT ACA T 3’ 19 58.0
Aph1387 probe 5’ CGG TGC GAC AAA GAT GCC AGC ACT AAT GCG
GCA CCG 3’
36 61.9 CAL Fluor Red 610/ BHQ-2
5ACTA1 primer 5’ AGA GCA AGA GAG GTA TCC 3’ 18 58.0 104 bp
3ACTA1 primer 5’ CTC GTT GTA GAA GGT GTG 3’ 18 57.7
ACTA1 probe 5’ CGC TGC CCT ATC GAG CAC GGC ATC ATC AC
GCA GCG 3’
35 62.4 Quasar 670/ BHQ-2
RecA3MB-com oligo 5’ ttG CGC CCC CTA GGA TAT CCG Ctt 3’ 24 67.9
TPKMB-com oligo 5’ tt tCG CGG CCG CTG GTC AAC AAC ACC ttt 3’ 29 61.5
AphMB-com oligo 5’ ttt CGC ATT AGT GCT GGC ATC TTT GTC ttt 3’ 30 61.9
ActinMB-com oligo 5’ tt tGT GAT GAT GCC GTG CTC GAT AGG ttt 3’ 29 62.4
*Italicized molecular beacon sequence depicts the arm sequences whereas the sequences marked by bold letters indicate probe region of molecular beacons
complementary to the target sequence.
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APH1387 amplicon using CAL Fluor Red 610 and
BHQ-2 quencher. The lengths of the probe sequences
were chosen so that they would form a stable hybrid
with the target at the annealing temperature (60°C) of
the PCR assay. The 5’ and 3’ arm sequences of the
molecular beacons were designed to form a stable hybrid
at 5 to 10°C above the annealing temperature of the
PCR assay. The fluorophores and quenchers were
chosen based on the specifications of the spectrofluoro-
metric thermal cycler platform on which the assays were
carried out and their compatibility in one multiplex
assay. The sequences of the molecular beacons used in
this study are listed in Table 1. A detailed protocol for
the synthesis and purification of molecular beacons can
be found at www.molecular-beacons.org. For this
study, molecular beacons were ordered from Biosearch
Technologies, CA. Initial standardization of PCR con-
ditions was conducted by using SYBR Green I dye
(Life Technologies, NY) and was followed by replacingSYBR Green with specific molecular beacon probes in the
assays.
Real-time PCR assays
Since genome sizes of B. burgdorferi and human are
1.5 Mb and 3.2 Gb respectively, 2 ng of B. burgdorferi
genomic DNA contains approximately 106 copies of recA
gene, while 350 ng of human genomic DNA contains
approximately 105 copies of ACTA1 gene. A 222 bp
fragment from recA gene of B. burgdorferi using RecF
and RecR primers and a 104 bp fragment from human
alpha actin A1 (ACTA1) gene using 5ACTA1 and
3ACTA1 primers were amplified by PCR in 0.2 ml
optical tubes using a Bio-Rad CFX96 Touch Real-time
PCR system (Bio-Rad Life Science Research, CA).
Amplification was performed in 25 μl reaction mixtures
containing AmpliTaq Gold PCR reaction buffer (Life
Technologies, NY) supplemented with 3 mM MgCl2,
500 ng/μl of bovine serum albumin, 250 μM of each
deoxynucleoside triphosphate (dNTP), 500 nM of each
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(Life Technologies, NY), and 100 nM each of RecA3 and
ACTA1 molecular beacon probe. Specificity of each
primer set and molecular beacon probe was first
checked in monoplex assays using the specific primers/
probe in the PCR. The primer/probe sets of other patho-
gen(s) were included as negative controls in these assay
(data not shown). For each amplification reaction, 5 μl
of the DNA template was used to minimize the variation
due to pipetting error. The amplification program con-
sisted of initial heating at 95°C for 5 minutes, followed by
50 cycles of heating at 95°C for 15 s, annealing and fluor-
escence detection at 60°C for 30 s, and polymerization at
72°C for 20 s. Similarly, amplification of a 141 bp ampli-
con from BmTPK gene using 5BmTPK and 3BmTPK
primers and a 152 bp amplicon of APH1387 gene using
5Aphagocyt and 3Aphagocyt primers were carried out in
the presence of human genomic DNA. Molecular beacon
probes, BmTPK and APH1387 were used for detection of
the respective amplicons. All primer and probe sequences
are listed in Table 1. Data were processed using the soft-
ware provided by the manufacturer.
Quadruplex real-time PCR assays
Quadruplex real-time PCR assay was performed in
conditions described above. Genomic DNA of B.
burgdorferi and human, and clones of BmTPK and
APH1387 were used as templates, and 500 nM each
of RecF and RecR primers and 5BmTPK and
3BmTPK primers, 250 nM each of 5Aphagocyt and
3Aphagocyt primers, 100 nM each of 5ACTA1 and
3ACTA1 primers, 100 nM each of RecA3, BmTPK,
APH1387, and ACTA1 molecular beacons were in-
cluded in each reaction.
For confirmation of the quadruplex assay in which
plasmids containing BmTPK and APH1387 were used,
we incorporated different concentrations of genomic
DNA of B. burgdorferi, B. microti and A. phagocytophi-
lum in the triplex real-time PCR. Human DNA control
was not included in these assays. Genome sizes of B.
microti and A. phagocytophilum are 6.5 Mb and 1.47 Mb,
respectively. Therefore, 106 copies of BmTPK and
APH1387 are calculated to be present in 8 ng and 2 ng of
genomic DNA, respectively. By using different relative
genomic copy numbers and the conditions described
above for quadruplex assay, consistent results vali-
dated our assay for simultaneous detection of all
three pathogens.
Borrelia speciation by real-time PCR assays
To differentiate three major species that cause Lyme dis-
ease in Europe, B. burgdorferi, B. afzelii and B. garinii,
asymmetric PCR assay was performed in 25 μl volume
such that the primer synthesizing the target strand ofthe molecular beacon was used in excess. The primers
for recA gene that are from the conserved region in all
three species, RecF3 and RecR3 were designed to amp-
lify a slightly longer 287 bp fragment in this asymmetric
PCR assay. The reaction mixture contained AmpliTaq
Gold PCR buffer supplemented with 3 mM of MgCl2,
500 ng/μl of bovine serum albumin, 250 μM of each
dNTP, 30 nM of RecF3 primer, 1000 nM of RecR3
primer, 50 nM of RecA3 molecular beacon and 5 units
of AmpliTaq Gold polymerase. The amplification pro-
gram consisted of initial heating at 95°C for 5 minutes,
followed by 60 cycles of heating at 95°C for 15 s, anneal-
ing and fluorescence detection at 60°C for 30 s, and
polymerization at 72°C for 20 s. It was immediately
followed by incubation at 25°C for 2 minutes to allow
annealing, and then a melt curve was included by
increasing the temperature from 25°C to 95°C in 1°C
step, with each step lasting 2 minutes while monitoring
the fluorescence. For analysis, the first derivative of
the denaturation profile was determined as described
previously [51].
Results
Optimization of molecular beacon probes for multiplex
PCR assays
To develop and optimize the multiplex assay that can
detect the presence of three tick-borne pathogens along
with the human DNA control in the patient sample, we
selected primers and molecular beacon probes that will
amplify and detect the amplicons under the same
selected PCR parameters. The absence of amplification
of the amplicons of each pathogen in the presence of
primers of other pathogens confirmed the specificity of
each set of primers for only the relevant pathogen
template DNA. The specificity of each molecular beacon
for its respective amplicon was first determined by gen-
erating the denaturation profiles for each probe in the
absence or presence of specific oligonucleotides (Figure 1
and Table 1). In the presence of the unrelated target or
in the absence of any target (buffer control), RecA3,
BmTPK, APH1387 and ACTA1 molecular beacons
remain in a closed state at low temperatures with fluo-
rophore and quencher held in close proximity by the
hairpin formation (Figure 1A). Molecular beacons
remain dark at this state. At temperature above the
melting temperatures of the stems (~68°C, 62°C, 62°C
and 63°C for RecA3, BmTPK, APH1387, and ACTA1,
respectively), the fluorophore separates from the quencher
resulting in increase in fluorescence intensity. The
molecular beacons bind to their respective targets at low
temperature resulting in the dissociation of the stem and a
high level of fluorescence. In contrast, at the melting
temperatures of probe-target hybrids (74°C, 76°C, 69°C
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Figure 1 Denaturation profile analysis of molecular beacon probes used in this study. Melting curves of the RecA3 molecular beacon
(A) in the presence of a complementary target sequence (green line), or in the absence of any target (buffer only control, dotted line) were
generated. The fluorescence intensities indicate that the molecular beacon exists either as a hybrid with its perfect complementary target
sequence, exhibiting high fluorescence from 25°C to 55°C, or in its free state in the form of a stem-loop structure with fluorescence quenched in
a temperature range of 25–65oC as depicted by the cartoons. At higher temperatures (more than 70oC) the molecular beacon probe denatures
and exhibits high fluorescence intensities in control. Similarly, probe-target hybrid also denatures at higher temperature releasing the target and
diminishing the fluorescence as the probe returns to hairpin-loop structure. A similar analysis of the BmTPK, APH1387 and ACTA1 molecular
beacon probes depicted a temperature and fluorescence profile (B, C, and D), which is similar to the RecA3 molecular beacon probe.
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results in the return of the probe to a stem-loop structure,
significantly diminishing the fluorescence. On further
increase in temperature, the beacons denature completely,
do not form a stem-loop structure, and hence, start to
emit some fluorescence (Figure 1A to 1D). Cartoons in
the Figure 1A depict different molecular beacon states at
particular temperatures, in the presence or absence of
specific targets in the reaction.
Detection of recA amplicon of B. burgdorferi in the
presence of human genomic DNA in a multiplex real-time
PCR assay
We had already optimized molecular beacons and PCR
conditions for quantitative detection of B. burgdorferi DNA
by real-time PCR [61]. To adapt the assay for diagnosis of
Lyme disease in the patients, we spiked the same quantity
of human DNA (350 ng genomic DNA or 105 ACTA1 copy
number) with a ten-fold dilution of genomic DNA of B.
burgdorferi. Since simultaneous detection of pathogen and
host PCR products is possible when molecular beaconprobes are tagged with different fluorophores, normalization
of the host DNA in patient sample will be convenient and
accurate method to quantify spirochete number, if needed.
In addition, accurate detection of host DNA in each sample
will ensure that the quality of the isolated DNA was suitable
for real-time PCR. To evaluate this premise, we included
primers and molecular beacons for both recA amplicon of
B. burgdorferi and ACTA1 amplicon of human DNA.
Amplification plots of the recA gene in the PCR assays
(Figure 2A), as detected by fluorescence intensity at the end
of each cycle at the annealing temperature, show that the
presence of 1 to 106 spirochetes can be detected using the
RecA3 molecular beacon consistently. A standard curve
(Figure 2B) generated by plotting the threshold cycle (Ct)
versus the log of the known initial copy numbers of B. burg-
dorferi indicates that the threshold cycle is inversely propor-
tional to the number of target molecules present in the
samples. A high coefficient of correlation (r2 = 0.999) be-
tween the B. burgdorferi copy number and the Ct obtained
from the standard curve indicates that this curve can accur-
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Figure 2 Molecular beacons can detect B. burgdorferi between 1 and 106 in a duplex assay, when human DNA was also included.
Amplification plots of recA and Actin A1 genes in PCR assays to estimate quantities of B. burgdorferi (A) and human (C) DNA are shown. Human
DNA (containing 105 Actin A1 gene copies) spiked with ten-fold dilutions of B. burgdorferi strain N40 ranging from 1 to 106 were used in the PCR
assays containing both RecA3 and ACTA1 molecular beacons. Sensitivity and specificity of the detection system is indicated by the ability of
RecA3 and ACTA1 molecular beacons to quantitatively detect the amplicons from both the recA and the ACTA1 genes in the same PCR assay
tubes. A high coefficient of correlation (r2 = 0.999) between the Ct values and the spirochete number obtained from the standard curve (B)
indicates that the molecular beacons can be used effectively to quantify spirochete burden in infected tissues using multiplex assay system.
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plex assays did not show significant differences (data not
shown). In addition, identical Ct values for ACTA1 in all
samples were detected, indicating that variation in the copy
number of B. burgdorferi genome, or the presence of the
human DNA in the sample does not affect sensitivity of de-
tection of amplicons of the pathogen or the host in the
multiplex assay (Figure 2A, 2C and data not shown).
TPK gene amplicon of B. microti can be detected
efficiently along with human ACTA1 in a multiplex PCR
assay
Two enzymes were identified to be important in central
metabolism of B. microti by genome sequencing of this
parasite [65], Lactate dehydrogenase (LDH) and TPK.
Only LDH is expressed during intra-erythrocytic multi-
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Figure 3 Molecular beacons can detect DNA between 1 and 106 B. m
Amplification plots of BmTPK and ACTA1 genes in PCR assays using the hu
from 1 to 106 of B. microti DNA copies were used to estimate quantities of
ACTA1 molecular beacons. The assay quantified amplicons from both the B
coefficient of correlation (r2 = 0.993) between the Ct values and the parasit
molecular beacons can be used effectively to quantify the parasite burden
optimized conditions.and TPK genes and initially used both plasmid clones as
templates for real-time PCR using SYBR green and also
respective molecular beacons (data not shown). How-
ever, only BmTPK showed promising results under con-
ditions optimized for amplification of Lyme spirochetes
and A. phagocytophilum gene amplicons. Therefore, we
conducted further investigation using the BmTPK gene
only. Ten-fold dilutions of plasmid containing BmTPK
gene, starting with 106 copies, were prepared in the
human DNA suspension (350 ng) containing 105 copies
of ACTA1 to use as template. Using 5BmTPK and
3BmTPK primers, BmTPK molecular beacon in addition
to human actin A1 primers and probe and following the
PCR conditions described in the methods section, ampli-
fication of TPK and ACTA1 amplicons were detected
and quantified. Although copy number from 106 to 10 of
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C
icroti in a duplex assay in the presence of human DNA.
man DNA representing 105 ACTA1 copies spiked with ten-fold dilutions
B. microti (A) and human (C) DNA by employing both BmTPK and
mTPK and the ACTA1 genes in the same PCR assay tubes. A high
e numbers obtained from the standard curve (B) indicates that the
in the infected human cells using multiplex assay system using the
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http://www.biomedcentral.com/1471-2180/13/295of single copy number of B. microti DNA was slightly
less reproducible. Standard curve (Figure 3B) depicts the
precision of these results with significant coefficient of
correlation (r2 = 0.993). Thus, it is expected that 10
copies of TPK will be detected consistently in this assay
with lower detection limit often possible. Overlapping
ACTA1 detection curves indicate the accurate detec-
tion and quantitation of the human amplicon since
the same concentration of human DNA was used in
different tubes for dilution of TPK-containing plasmid
(Figure 3C).Specific detection of APH1387 amplicon in the presence
of human DNA using molecular beacon probes in a
multiplex PCR assay
A. phagocytophilum is an obligate intracellular patho-
gen that multiplies within a vacuole inside the host cells
and avoids fusion of this vacuole with lysosome.
APH1387 of A. phagocytophilum was identified as the
first protein that localizes to the vacuolar membrane
containing this pathogen [66]. Since the gene is uniquely
present in A. phagocytophilum and is highly conserved
in various strains, it will allow detection of this pathogen
in patient samples irrespective of the presence of differ-
ent infecting strains. Therefore, we selected this ampli-
con for detection of this bacterial pathogen by real-time
PCR. By using the strategy used for TPK gene containing
plasmid for B. microti described above, APH1387 con-
taining plasmid was diluted in human DNA and PCR
was conducted using 5Aphagocyt and 3Aphagocyt
primers and Aph1387 molecular beacon. Primers for hu-
man actin A1 gene amplicon and ACTA1 molecular
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Figure 4 Molecular beacons can detect DNA between 1 and 106 A. ph
present. Amplification plots of APH1387 and ACTA1 genes in PCR assays u
ten-fold dilutions from 1 to 106 plasmid copies containing APH1387 were u
DNA by employing both Aph1387 and ACTA1 molecular beacons. The assa
in the same PCR assay tubes. A high coefficient of correlation (r2 = 0.985) b
standard curve (B) indicates that the molecular beacons can quantify burd
multiplex assay system under the standardized conditions in a sensitive an
than one.Conditions for PCR were identical to those used for
Lyme spirochetes recA and B. microti TPK gene amplifi-
cations. Interestingly, in repeated experiments, APH1387
detection limit was similar to that of BmTPK (Figure 4A)
and sensitivity of detection appears to be slightly lower
(>1 bacterial amplicon) than the detection limit for recA
amplicon of Lyme spirochetes (~1). Indeed, the curves
for 10 and 1 copies of the gene were very close to each
other. Again, the results were reflected in the standard
curve and slightly lower coefficient of correlation (r2 =
0.985) (Figure 4B) than that for recA (r2 = 0.999). Sen-
sitivity of detection of human ACTA1 amplicon was
maintained (Figure 4C) similar to that in the multi-
plex assays described for recA and BmTPK amplicons
above.Simultaneous detection of recA of Lyme spirochetes, TPK
of B. microti and APH1387 amplicon of A.
phagocytophilum along with human actin A1 in a
quadruplex PCR assay
Since coinfection of ticks with Lyme disease spiro-
chetes and emerging pathogens Babesia species and A
phagocytophilum has been increasing in the endemic
regions of tick-borne illnesses, it is very likely that
these coinfections will continue increasing steadily in
humans in the near future. Therefore, development of
a single multiplex real-time PCR assay for simultan-
eous detection of all three tick-borne pathogens in
the patient samples in a sensitive and specific manner
is expediently warranted. Even though cloned genes
of both pathogens, B. microti and A. phagocytophi-
lum, in plasmids could be detected and quantitated
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sed to estimate quantities of A. phagocytophilum (A) and human (C)
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en of this intracellular pathogen in the infected human cells using
d specific manner even though sensitivity of detection is slightly higher
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http://www.biomedcentral.com/1471-2180/13/295if the sensitivity is maintained when the DNA of all
three pathogens is present in the assay. To achieve
this goal, we standardized conditions such that gen-
omic DNA of B. burgdorferi and plasmids containing
BmTPK and APH1387 genes were serially diluted in
human DNA containing 105 copies of ACTA1 gene.
Sensitivity of detection of recA amplicon was not
affected by the presence of DNA of other two patho-
gens (Figure 5A). By increasing the concentration of
molecular beacons in the quadruplex assay mixture,
we were able to improve the sensitivity of detection
of A. phagocytophilum APH1387 amplicons such that
one copy number was clearly distinguishable from 10
DNA copies (Figure 5B). However, based upon Pois-
son distribution, an average single copy of the tem-
plate is not expected to be present in all samples
consistently. Lack of amplification of predicted one
copy of B. microti in this assay demonstrates this
probability (Figure 5C). This assay demonstrated that
amplicons from all three pathogens along with the
control human ACTA1 gene amplicon can be de-
tected accurately in one multiplex assay (Figure 5D)
and sensitivity of detection of different pathogens was






























































Figure 5 Inclusion of three tick-borne pathogens in the presence of h
sensitivity of their detection. Conditions for a quadruplex PCR assay wer
beacons for respective amplicons were present in the same tube along wit
two bacterial pathogens, extracellular spirochete B. burgdorferi (A) and obli
intracellular parasite, B. microti (B), was not affected in this quadruplex assa
diagnosis of all three tick-borne pathogens in the patients, especially in the
reaction will offer as control for human DNA (D) and quality of DNA prepa
infecting organism.will lead to expansion of this assay to the patient
samples from endemic regions in the future.Sensitivity of detection of emerging pathogens B. microti
and A. phagocytophilum DNA is retained in the presence
of excess of B. burgdorferi DNA
Depending on the prevalent conditions in a particular
endemic region, quantities of these emerging patho-
gens may vary in the patient samples. Therefore, we
further assessed the sensitivity of the assay for detec-
tion of B. microti and A. phagocytophilum in excess
of B. burgdorferi DNA. We used B. burgdorferi gen-
omic DNA/recA copy number (106) along with gen-
omic DNA equivalent to 103 genomic copies of each
of B. microti and A. phagocytophilum (Figure 6A). Ac-
curacy and sensitivity of detection of B. microti and
A. phagocytophilum was not affected by 103-fold ex-
cess of B. burgdorferi genomic DNA, validating the
potential of our multiplex assay for diagnosis of all
three tick-borne infections even if one pathogen is
present in excess. Such excess of B. burgdorferi may
be present in the synovial fluid or skin biopsy sam-
























































uman DNA in a single quadruplex assay does not affect the
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gate intracellular pathogen A. phagocytophilum (C), along with the
y, indicating that the assay can be extended for simultaneous
endemic regions. Detection of the ACTA1 amplicon in the same























Figure 7 Denaturation profiles can distinguish three major
Lyme spirochete species. Amplification of 287 bp amplicons
from B. burgdorferi, B. afzelii and B. garinii by real-time PCR using
conserved primers was followed by a denaturation profile analysis.
SNPs in the molecular beacon-binding region of B. burgdorferi,
B. afzelii and B. garinii resulted in at least 4°C melting temperature
difference between the species such that RecA3 molecular beacon
was able to distinguish all three Borrelia species when first derivative



















































Figure 6 Sensitivity of detection of tick-borne pathogens B. burgdorferi, B. microti, and A. phagocytophilum are not affected in the
presence of excess of other pathogens. (A) One thousand copies of B. microti and A. phagocytophilum genomic DNA were accurately
detected in the triplex assay despite 103-fold excess of copy number of B. burgdorferi genomic DNA. (B) Detection of ten B. burgdorferi recA
amplicon copies was not affected in the triplex assay even in the presence of 100-fold excess of copy number of both B. microti and
A. phagocytophilum genomic DNA.
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http://www.biomedcentral.com/1471-2180/13/295B. burgdorferi can be accurately detected even in the
100-fold excess of B. microti and A. phagocytophilum
genomic DNA
Blood is primarily used as conduit by Lyme spirochetes
to disseminate to various tissues such that usually only a
few B. burgdorferi are present in the blood at any given
time. Therefore, it is likely that intracellular blood-borne
pathogens A. phagocytophilum and B. microti could be
present in higher numbers in the cells even if the patient
has coinfection with B. burgdorferi. To determine
whether detection of B. burgdorferi will be affected by
the presence of higher levels of bacteremia and
parasitemia due to A. phagocytophilum and B. microti,
respectively, we mixed genomic DNA of all three
pathogens such that the copy number of BmTPK and
APH1387 was 100-fold higher than that of the recA
copies of B. burgdorferi. Interestingly, we were able to
consistently detect ten copies of recA per one thousand
copies of BmTPK and APH1387 in a multiplex assay
(Figure 6B). These results in the Figure 6 demonstrate
that irrespective of the levels of each pathogen quantity
relative to the other two pathogens, our multiplex assay
can accurately detect and even quantify each pathogen
in the mixture.
Differentiation of Lyme spirochetes using denaturation
curve analysis
The PCR assay for B. burgdorferi described in Figure 2
failed to both amplify and detect B. afzelii and B. gar-
inii amplicons efficiently and differentiate these three
Lyme spirochetes. Inefficiency of the PCR amplifica-
tion for B. afzelii and B. garinii amplicons is likely
due to the presence of SNPs found in the RecF and
RecR primers binding sites in these two species. RecF
and RecR primers were designed based upon B. burg-
dorferi sequence. Therefore, conserved primers RecF3
and RecR3 were selected for amplification of a287 bp size amplicon of the recA gene by PCR all
three species. These primers amplified the gene frag-
ment from all three species efficiently. To clearly dis-
tinguish three Borrelia species using the denaturation
profiles, we conducted asymmetric PCR in which
RecR3 primer that synthesizes DNA strand targeted
by molecular beacon probe was used in excess. This
significantly increases the availability of amplified
DNA target for the RecA3 probe to bind. SNPs that
are present in the probe-binding region of the ampli-
con affect the temperature required to denature the
probe-target hybrid. Indeed, denaturation profile
obtained after asymmetric PCR completion was able
to distinguish three Borrelia species, with a melt peak
of 66°C for B. burgdorferi, 59°C for B. afzelii, and 55°
C for B. garinii (Figure 7).
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B. burgdorferi in human blood
In this final assay, we determined if the presence of
spirochetes could be detected in the human blood. DNA
isolated from blood spiked with live spirochetes, with or
without culture in BSKII + RS medium, was used as
template for real-time PCR for recA amplicon of B. burg-
dorferi (Figure 8A and 8B). Detection of spirochete DNA
did not significantly improve after culture when the
number was close to 1 per 1.5 ml of blood. The presence
of 10 spirochetes in 1.5 ml of blood could be consist-
ently detected albeit without accurate quantification irre-
spective of blood culture (data not shown). Quantitation
of 100 spirochetes in 1.5 ml of blood or 100 μl of total
DNA isolated from spiked blood (i.e. 5 spirochetes per
5 μl of template used in PCR) was accurate and consist-
ent both with and without culture in BSKII + RS. Thus,
the sensitivity of detection in this assay remains better
than in any other nucleic acids based assays for Lyme
spirochetes described previously.
Discussion
Lyme disease is prevalent in both the Unites States and
Europe. Although B. burgdorferi sensu stricto is docu-
mented to be the spirochete responsible for Lyme
disease in the USA, B. afzelii and B. garinii affect a
significant population in Europe and Asian countries
[67,68]. Emerging pathogenic disease anaplasmosis
caused by A. phagocytophilum is one of the most preva-
lent life-threatening tick-borne diseases and has recently
become notifiable in the United States [14,69]. Further-
more, B. microti in the USA and B. divergens in Europe
have become important tick-borne parasitic diseases and
infections with these pathogens are increasing steadily
[10,70]. Another major upcoming problem is blood
transfusion associated babesiosis that can remain

























Figure 8 Multiplex assay using 1.5 ml human blood spiked with seria
B. burgdorferi. (A) B. burgdorferi were detected consistently in all replicate
of total 100 μl DNA recovered from 1.5 ml spiked blood was isolated witho
affected in the multiplex assay, as expected (data not shown). (B) Improvem
of Lyme spirochetes spiked human blood in BSKII + RS medium at 33°C waa blood safety threat [71-74]. Serological tests used for
diagnosis of Lyme disease, anaplasmosis and babesiosis
cannot be used early in infection before the adaptive
immune response is established. In addition, due to
persisting antibodies long after disease has resolved and
patient is cured, these tests cannot be used to detect
active infection and they fail as test of cure. These diffi-
culties add to the disadvantage of using the indirect
serological diagnostic tests for tick-borne infectious
diseases. Furthermore, species and strains differences in
different geographical regions could further diminish the
efficient diagnosis with the available commercial sero-
logical kits [37]. In addition, microscopic examination
for diagnosis of anaplasmosis and babesiosis is both
time-consuming and labor intensive making them
quite expensive. Hence, there is a desperate need to
develop efficient tests for detection of the presence of
these pathogens in a cost-effective and efficient
manner.
The presence of nucleases in serum and in other body
fluids ensures clearance of nucleic acids when pathogens
are eliminated by treatment with antimicrobials [50,75,76].
Therefore, nucleic acid based tests are now becoming
popular for diagnosis of various infectious diseases
[51,52,77]. Indeed, these assays are ideal as the tests of
cure for various diseases. Early detection of infection by
Borrelia species, A. phagocytophilum and Babesia species
using nucleic acid based techniques can lead to successful
treatment of the illnesses in a timely manner. We previ-
ously developed a sensitive and accurate quantitative real-
time PCR assay using molecular beacons for mouse tissues
[61]. MassTag PCR has been employed to detect coinfec-
tion of ticks collected from different sites in New York
with B. burgdorferi, A. phagocytophilum and B. microti
[6,78] and quantitative PCR has also been employed
recently for patient samples [79]. A pilot study, using the
























l dilutions of Lyme spirochetes can recover and quantitate
s when ≥5 bacteria were present per ~75 μl of blood, i.e., when 5 μl
ut additional manipulation. Detection of human Actin A1 was not
ent in recovery and quantitation of B. burgdorferi after 48 h culture
s not significant.
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efficiency in detection of early Lyme disease and could
often distinguish different strains/genotypes involved [80].
Recently, a real-time PCR test using 18S rRNA gene of B.
microti was successfully used by employing small DNA
groove probe for specific detection of the presence of this
parasite with a sensitivity of ~100 gene copies per 5 μl of
the patients’ blood [53]. However, all these tests have yet
to be fully refined to employ them for diagnosis purpose
in a cost-effective manner. In this study, we have expanded
the use of specific molecular beacon probes in real-time
PCR for either simultaneous detection of three Lyme
spirochete species and distinguishing them using the
denaturation profile analysis or detection of the pres-
ence of A. phagocytophilum and B. microti along with
B. burgdorferi in the sample using a single assay. Use
of our duplex versus a multiplex assay according to
need will be efficient and less expensive assay for
diagnosis of multiple tick-borne diseases.
Our optimized multiplex assay could accurately detect
and quantify a single spirochete recA gene copy spiked
in the human DNA. The presence of high concen-
trations of human genomic DNA (containing 105 copies
of ACTA1 gene) did not affect accuracy of the assay
(Figure 2) as also shown by almost perfect coefficient of
correlation (r2 = 0.999) between threshold cycle and copy
number of B. burgdorferi DNA. In addition, an asym-
metric PCR was able to detect B. burgdorferi, B. afzelii
and B. garinii efficiently. Furthermore, it is possible to
distinguish these three species using meting curve fol-
lowing the PCR assay (Figure 7). Using similar strategy,
additional Borrelia species, such as emerging B. miyamo-
toi, can be identified in the future with a little tweaking
of the assay.
The best time to develop an efficient diagnostic assay
is when infections by a particular organism start emer-
ging among human or animal populations, environment
or in the vectors. This ensures that a well-standardized
and efficient diagnostic test is available when significant
population starts getting affected by the emerging patho-
gen. The infections of tick populations by two tick-borne
pathogens, A. phagocytophilum and Babesia species have
been increasing in both Europe and the United States,
and the cases of infections by these emerging pathogens
are also getting reported at a higher numbers in both
continents [1,2]. Indeed, coinfections with these tick-
borne pathogens have started appearing in the patients,
and result in more severe illnesses than those observed
when the patient is infected by each pathogen indivi-
dually [27,81]. Therefore, we decided to expand our
real-time PCR approach to include detection of these
two emerging pathogens. Optimized PCR conditions for
each emerging pathogen, B. microti and A. phagocytophi-
lum BmTPK and APH1387 gene amplicons, respectivelyalong with the human ACTA1 amplicon (Figures 3 and 4)
worked well even in quadrupex assay in which serially
diluted genomic DNA of B. burgdorferi and human
could be accurately detected in addition to BmTPK
and APH1387 containing plasmid DNA (Figure 5).
Similarly, a 100-fold excess of B. microti and A. pha-
gocytophilum copy number did not affect accuracy of
detection of B. burgdorferi (Figure 6B). Moreover, this
test could detect as few as 103 copies of both APH1387
and BmTPK in mixed genomic DNA presence containing
an excess (upto 103-fold higher or 106 copy number)
of B. burgdorferi DNA indicating the sensitivity and
accuracy of the assay is maintained irrespective of the
different load of the pathogens presence in the sam-
ple (Figure 6A). These results demonstrate that we
can use this assay to efficiently and relatively quickly
detect individual pathogens, such as B. microti in blood
bank samples using the approach used in the Figure 3. We
can also diagnose coinfections with two or three patho-
gens in the endemic regions for these tick-borne diseases
using the quadruplex assay (Figures 5 and 6). Finally,
success of our assay with B. burgdorferi spiked human
blood indicates that we will be able to use it for diagnostic
purpose in human patients (Figure 8). Although real-time
PCR and other techniques have been tested for identifica-
tion of Lyme spirochetes and other tick-borne pathogens
individually, albeit primarily in ticks [6,78,80,82-86], this is
the first comprehensive study to develop assay for sensi-
tive detection of three tick-borne pathogens simultan-
eously. These assays can be easily adapted for the patient
samples in the future with a little modification, if needed.
Furthermore, with the recent emergence of ticks infected
with deer tick virus and Powassan virus lineages in New
York and Connecticut in the United States and several
European countries [87-89], it will be useful to include an
assay for their diagnosis. Our assay could easily be
extended to include the most prevalent virus amplicon
after an addition reverse transcription step. Since most
real-time PCR machines are capable of detecting five
fluorophore with non-overlapping spectrofluorometric
spectra and we have only used four in our assay, we antici-
pate that achieving this goal will be relatively simple. In
summary, the ability of the assay described here to detect
multiple tick-borne pathogens simultaneously will be a
boon for health professionals to design more effective
treatment regimes for coinfections when this assay is
approved for mass application.
Conclusions
Optimized conditions and PCR parameters, including
the amplicons of the conserved genes present in
Lyme spirochetes, A. phagocytophilum and the tick-
borne parasite B. microti, and molecular beacon
probes tagged with distinct fluorophores, can detect
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presence of any pathogen did not affect sensitivity of
detection of the other pathogen present in lower
dose. The real-time PCR assay described here can be
used both; to detect coinfections with more than one
tick-borne pathogen in the endemic regions of the
USA and the European countries as well as to detect
each pathogen individually with equal efficiency. Since
transfusion-associated babesiosis cases and fatalities
are increasing steadily, the assay can also be used for
detection of Babesia species and A. phagocytophilum
in blood donated to the blood banks after minor
modifications. The assay will be used in the future for
diagnosis of tick-borne diseases after further optimization
with patient samples.
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